We're off to the races!

Novo Nordisk files for regulatory approval of turoctocog alfa for haemophilia A in the US and EU

Novo Nordisk today announced the submission of the regulatory application for turoctocog alfa (NN7008) to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Turoctocog alfa is a third-generation recombinant coagulation factor VIII intended for prevention and treatment of bleeding in people with haemophilia A.“We are very excited about having reached […]

en_USEnglish